Actively Recruiting
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Led by Alnylam Pharmaceuticals · Updated on 2026-05-14
44
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
CONDITIONS
Official Title
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Is willing and able to complete all study assessments
You will not qualify if you...
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than upper limit of normal (ULN)
- Has total bilirubin greater than upper limit of normal (ULN)
- Has history of invasive infection by an encapsulated organism
- Has known complement or immunologic deficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Trial Site
London, United Kingdom, NW10 7EW
Actively Recruiting
Research Team
C
Clinical Trial Information Line
CONTACT
C
Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here